HOME >> BIOLOGY >> NEWS
New antibacterials being developed to tackle MRSA superbug

A novel antibacterial medicine that kills the superbug MRSA is being developed under a new scheme launched by the Wellcome Trust. The Seeding Drug Discovery initiative is aimed at catalysing the development of new drugs in areas of unmet need.

Prolysis, an R&D company based in Oxford, has received one of three inaugural Seeding Drug Discovery awards for its new antibacterial compounds aimed at tackling life-threatening, drug-resistant infections caused by staphylococci, including MRSA.

The bacterium Staphylococcus aureus can infect wounds, including those resulting from medical procedures conducted in hospitals. It may then spread further into the body and cause serious infections such as blood poisoning. Methicillin-resistant Staphylococcus aureus, or MRSA, is a form of the bacterium that is resistant to the drug methicillin and a number of other antibiotics and tends to be more difficult to treat.

"The so-called superbug MRSA is fast becoming untreatable with the currently available antibiotics," says Dr Ted Bianco, Director of Technology Transfer at the Wellcome Trust. "We urgently need a new generation of antibacterial medicines to stop its spread through hospitals, nursing homes and the wider community."

The compounds being developed by Prolysis under the award from the Wellcome Trust block the ability of the MRSA bacteria to divide and multiply. They do this by inhibiting the function of the bacterium's FtsZ protein, which is essential for cell division. FtsZ is not found in humans so targeting a unique protein like this should reduce the likelihood of side-effects in patients. Because of the novel mode of action of the new class of compounds, the levels of resistance in the bacterial population should be extremely low if a new drug was to emerge from this programme.

"The antibiotic that we are developing is far more selective than those currently in use, targeting only staphylococcal infections," says Dr Lloyd
'"/>

Contact: Craig Brierley
c.brierley@wellcome.ac.uk
44-207-611-7329
Wellcome Trust
14-Jan-2007


Page: 1 2

Related biology news :

1. Universal flu vaccine being tested on humans
2. Reproductive speed protects large animals from being hunted to extinction
3. DNA layer reduces risk of reserve parts being rejected
4. Are scientists making progress in being able to regenerate bone tissue?
5. Its not easy being green
6. Its not easy being green
7. Accelerating loss of ocean species threatens human well-being
8. Accelerating loss of ocean species threatens human well-being
9. Fat stem cells being studied as option for breast reconstruction
10. Nanotechnology being used to improve biocompatibility of human prosthetics and implants
11. Progress being made in exploring potential use of stem cells to treat heart disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/21/2019)... Mass. (PRWEB) , ... January 20, 2019 , ... Energetiq ... its parent company, Hamamatsu Photonics, at the SPIE BIOS and SPIE Photonics West events ... and Hamamatsu will be in booth #8526 at Bios and in booth #941 at ...
(Date:1/20/2019)... ... January 16, 2019 , ... January has been a record-breaking month ... Not only has the company already hosted several of its signature cooking classes and ... and Janssen Pharmaceuticals, later this month. , Since 2008, Lajollacooks4u’s team-building events have ...
(Date:1/14/2019)... ... January 14, 2019 , ... CellMax Life , ... in blood, will present new findings at the ASCO Gastrointestinal Cancer Symposium in ... The results from this study show CellMax Life’s blood test, based on its ...
Breaking Biology News(10 mins):
(Date:2/2/2019)... ... January 31, 2019 , ... ... clinical use of perinatal tissue by applied stem cell research expert and Amazon ... Signature Cord is a flowable umbilical cord tissue allograft that originates from the ...
(Date:1/30/2019)... ... January 29, 2019 , ... Actus Therapeutics, a ... of the first patient in a phase 1/2 clinical study of ACTUS-101 in ... high morbidity and often leads to premature death. There are variable rates ...
(Date:1/30/2019)... ... January 30, 2019 , ... In ... tasting 5StarWines to promote and give recognition to producers whose work focuses entirely ... selection takes place in Verona, Italy, contemporaneously to the 5StarWines blind tasting organized ...
(Date:1/24/2019)... , ... January 23, 2019 , ... ... microbial genomics, has awarded microbiome research support in study design, planning, sample collection, ... of Medical Sciences, St. Augustine Campus in Trinidad led by Dr. Elaine Monica ...
Breaking Biology Technology:
Cached News: